



Non-Animal Platform for Nanoparticle- Based Delivery across the Blood-Brain Barrier Interface with Vehicle Evolution

www.nap4dive.eu

Funded by the European Union. Views and opinions expressed are however those of the author(s) only and do not necessarily reflect those of the European Union or the European Health and Digital Executive Agency (HADEA). Neither the European Union nor the granting authority can be held responsible for them

Clinical context & scientific challenge




- **Brain diseases** affect 179 million Europeans, costing 800 billion EUR per year
- **Blood-brain barrier (BBB)** is the major obstacle in efficiently delivering drugs for treatment (only 5% reaching the brain)
- Solution might be the use of **drug delivery vehicles**
 - **Nanoparticles** studied as a solution for BBB-crossing for 30 years, but only 30 NP systems in clinical trials, and majority have already failed
- **Preclinical models (mostly mice) harm animals** and do not successfully mimic human BBB
 - 850 000 animals used annually in the EU in the nervous system research

NAP4DIVE Solution



- We develop two complementary non-animal tools for biomedical research and drug development:
 1. “**Nanoparticle Design Simulator**”, *in silico* model based on machine-learning
 2. High-throughput “**Blood-brain barrier-on-Chip**” model using human cells to mimic human physiology
- This will establish reliable non-animal alternatives for testing, explaining, and predicting nanoparticle-based drug delivery across the human blood-brain barrier.

NAP4DIVE overview



BBB = blood-brain barrier
HTA = health technology assessment
NP = nanoparticle

Created in <https://BioRender.com>

Consortium expertise



NP design library,
digital simulator



Cell-NP
interaction



Blood-brain barrier-
on-Chip



finnadvance



Demonstration &
validation



NPs (synthetic &
biological)



UNIVERSITY OF
GOTHENBURG

Health technology
assessment



NP upscaling &
manufacturing



Ethics



Management &
dissemination



Support structure









- Ethics board
 - Monitor and report ethics issues (AI and animal research)
 - Meet with partners once a year
 - Ensure all activities follow ethical principles
- External Advisory Board
 - Provide advise and guidance on technological, exploitation, regulatory and clinics aspects of project progress
 - Meet with consortium yearly and provide advice *ad hoc*
- Joint Research Centre (JRC)
 - Provide advice on standardization aspects of developed technologies

NAP4DIVE Building blocks




- Nanoparticle (NP) design library: characterization and synthesis
- Digital nanoparticle design simulator
- Blood-Brain Barrier-on-Chip
- Demonstration and validation: Identifying safe and efficacious nanoparticles: Triaging on the Blood-Brain Barrier Chip
- Market readiness, health technology assessment
- Ethics

NP characterization and synthesis


Property-functionality relationship		
Nanoparticle formulations	Nanoparticle properties and protein corona	Nanoparticle-BBB interactions
<ul style="list-style-type: none"> Synthetic nanoparticles <ul style="list-style-type: none"> Different core materials Different sizes Different surface properties  <ul style="list-style-type: none"> Biological nanoparticles <ul style="list-style-type: none"> Different cell sources 	<p>Nanoparticle characterization</p> <ul style="list-style-type: none"> Size, charge, density Surface ligand, drug load <p>Protein corona</p> <ul style="list-style-type: none"> Static (bulk) Dynamics (surface bound)  <p>Composition of protein corona</p> <ul style="list-style-type: none"> Effect on nano-bio interactions 	<ul style="list-style-type: none"> Dynamic cell membrane interactions  <ul style="list-style-type: none"> Dynamic cell interactions and uptake 
DLS, NTA, TEM, SEM	WGSM, MP-SPR, Mass spectrometry	QCM-D, MP-SPR, WGSM

Digital NP design simulator




Blood-brain barrier-on-Chip

Optimization for the test of nanoparticles and extracellular vesicles



Demonstration and validation

Identifying safe and efficacious NPs, triaging on the BBB-on-Chip



Primary
screen

NP libraries applied to BBB-on-Chip to test for permeability

Secondary
screen

Permeable NPs tested for cargo delivery

Tertiary
screen

NPs tested for safety and toxicity in dose response and time course studies

in vivo
validation


5 NPs selected for downstream *in vivo* studies in mouse models

Market readiness & Health Technology Assessment




HTA Core Model domains

1. Description and technical characteristics of the technology (TEC)
2. Health problem and current use of the technology (CUR)
3. Clinical Effectiveness (EFF)
4. Safety (SAF)
5. Cost and economic evaluation
6. Ethical analysis
7. Organisational aspects
8. Patient and social aspects
9. Legal aspects



Ethics



Contacts



Prof. Cecilia Sahlgren

Åbo Akademi University

Coordinator

coordinator@nap4dive.eu

Follow us!



LinkedIn



Website



Mariana Pacheco Blanco, Ph.D.

AMIRES

Project and dissemination manager

social@nap4dive.eu



UNIVERSITY OF
GOTHENBURG



CHALMERS
UNIVERSITY OF TECHNOLOGY



finnadvance



TU/e EINDHOVEN
UNIVERSITY OF
TECHNOLOGY

TUDelft

THANK YOU!

AstraZeneca



Åbo Akademi
University



AMIRÈS

betthera

HansaBioMed
Life Sciences